The mean <i>z</i> scores for the first recorded values of height, weight, and body mass index in the patients' medical records were -4.25, -1.04, and 0.41 for MPS I (<i>n</i> = 9), -2.31, 0.19, and 0.84 for MPS II (<i>n</i> = 49), -0.42, 0.08, and -0.12 for MPS III (<i>n</i> = 27), -6.02, -2.04, and 0.12 for MPS IVA (<i>n</i> = 30), and -4.46, -1.52, and 0.19 for MPS VI (<i>n</i> = 14), respectively.
Although enzyme replacement therapy has become available for some MPS types (MPS I, MPS II and MPS VI), this treatment is not efficient when neurological symptoms occur, especially in MPS III (Sanfilippo disease).
An incidence of approximately 1 in 107,000 live births was obtained for MPS IH (Hurler phenotype); 1 in 320,000 live births (1 in 165,000 male live births) for MPS II (Hunter Syndrome); 1 in 58,000 for MPS III (Sanfilippo Syndrome); 1 in 640,000 for MPS IVA (Morquio Syndrome type A), and 1 in 320,000 for MPS VI (Maroteaux-Lamy Syndrome).